

NCTN Breast Cancer Trials Portfolio (Open as of 7/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

	Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
	S2212 (SCARLET) TNBC T2-4/N0/M0, or T1-3/N1-2/M0 S2206 HR+/HER2- Stage II or III	A012103 (OptimICE-PCR) TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab A012303 (ShortStop-HER2) HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade	NRG-BR009 (OFFSET) HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients EA1242 (RxFINE-Low) HR+/HER2- pT0-3/N0-3/M0, Oncotype Recurrence Score ≤ 25, Postmenopausal patients	EAY191 (ComboMATCH)

Legend by Subtype Status

Green = TNBC

Orange = HER2+
(Any HR status)

Purple =
HR+ and HER2-

Pink = Cross-
disease trial

NCTN Breast Cancer Trials (Open as of 7/15/2026)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012303	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
EA1242	III	A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS $\leq$ 25 (RxFINE-Low)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score $\leq$ 25 (OFFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>